Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1. Its clinical program also comprises MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to solid tumors. In addition, the company is developing preclinical product candidates for various solid tumor indications. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MACK
CUSIP59032810
Phone617-441-1000
Debt
Debt-to-Equity RatioN/A
Current Ratio4.40
Quick Ratio4.40
Price-To-Earnings
Trailing P/E Ratio-1.62
Forward P/E Ratio-1.93
P/E GrowthN/A
Sales & Book Value
Annual Sales$144.27 million
Price / Sales0.85
Cash FlowN/A
Price / CashN/A
Book Value$7.22 per share
Price / Book1.27
Profitability
EPS (Most Recent Fiscal Year)($5.66)
Net Income$472.02 million
Net MarginsN/A
Return on Equity-64.89%
Return on Assets-40.80%
Miscellaneous
Employees72
Outstanding Shares13,340,000
Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions
What is Merrimack Pharmaceuticals' stock symbol?
Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."
When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?
Shares of Merrimack Pharmaceuticals reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Merrimack Pharmaceuticals' earnings last quarter?
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) posted its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.28) by $0.05. View Merrimack Pharmaceuticals' Earnings History.
When is Merrimack Pharmaceuticals' next earnings date?
What price target have analysts set for MACK?
1 brokers have issued 12-month price targets for Merrimack Pharmaceuticals' shares. Their forecasts range from $12.00 to $12.00. On average, they expect Merrimack Pharmaceuticals' share price to reach $12.00 in the next year. View Analyst Ratings for Merrimack Pharmaceuticals.
Who are some of Merrimack Pharmaceuticals' key competitors?
Some companies that are related to Merrimack Pharmaceuticals include Aurinia Pharmaceuticals (AUPH), Synergy Pharmaceuticals (SGYP), Depomed (DEPO), Cytokinetics (CYTK), ZIOPHARM Oncology (ZIOP), ArQule (ARQL), Concert Pharmaceuticals (CNCE), Albireo Pharma (ALBO), Mersana Therapeutics (MRSN), Verastem (VSTM), Dermira (DERM), Sinovac Biotech (SVA), ZEALAND PHARMA/S (ZEAL), Evelo Biosciences (EVLO) and Unum Therapeutics (UMRX).
Who are Merrimack Pharmaceuticals' key executives?
Merrimack Pharmaceuticals' management team includes the folowing people:
- Dr. Richard Peters, Pres, CEO & Director (Age 55)
- Ms. Jean M. Franchi, CFO & Treasurer (Age 52)
- Mr. Jeffrey A. Munsie, Gen. Counsel, Head of Corp. Operations & Sec. (Age 41)
- Dr. Daryl C. Drummond Ph.D., Head of Research (Age 49)
- Dr. Sergio L. Santillana, Chief Medical Officer (Age 55)
Has Merrimack Pharmaceuticals been receiving favorable news coverage?
Media stories about MACK stock have trended somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Merrimack Pharmaceuticals earned a media sentiment score of 0.11 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 45.24 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Merrimack Pharmaceuticals' major shareholders?
Merrimack Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.04%), FMR LLC (4.51%), Rubric Capital Management LP (3.57%), Dimensional Fund Advisors LP (2.77%), Northern Trust Corp (1.20%) and Newtyn Management LLC (1.06%). Company insiders that own Merrimack Pharmaceuticals stock include Birgit M Schoeberl, Daryl C Drummond and Ulrik B Nielsen. View Institutional Ownership Trends for Merrimack Pharmaceuticals.
Which major investors are selling Merrimack Pharmaceuticals stock?
Which major investors are buying Merrimack Pharmaceuticals stock?
How do I buy shares of Merrimack Pharmaceuticals?
Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merrimack Pharmaceuticals' stock price today?
One share of MACK stock can currently be purchased for approximately $9.15.
How big of a company is Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals has a market capitalization of $122.09 million and generates $144.27 million in revenue each year. The biopharmaceutical company earns $472.02 million in net income (profit) each year or ($5.66) on an earnings per share basis. Merrimack Pharmaceuticals employs 72 workers across the globe.
How can I contact Merrimack Pharmaceuticals?
Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]
MarketBeat Community Rating for Merrimack Pharmaceuticals (MACK)
MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe MACK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days.
